Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107330 | 0.89 | PPARG (0.59) | PPARG | |
| SCHEMBL5105449 | 0.86 | PPARG (0.49) | PPARGPTGDR2SLC16A3SLC16A1MCTS1 | |
| SCHEMBL5119862 | 0.83 | PPARG (0.52) | PPARGPTGDR2PPARD | |
| SCHEMBL27737192 | 0.81 | PPARG (0.63) | PPARGPTGDR2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5106773 | 0.80 | PPARG (0.65) | PPARGP2RX7 | |
| SCHEMBL5119835 | 0.80 | PPARG (0.74) | PPARG | |
| SCHEMBL3195607 | 0.80 | PPARG (0.66) | PPARGPTGDR2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5120324 | 0.78 | PPARG (0.61) | PPARGPTGDR2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5114919 | 0.77 | PPARG (0.61) | PPARG | |
| SCHEMBL5119377 | 0.76 | PPARG (0.82) | PPARGPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | claimed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885PTGDR2 2631/4885SLC16A3 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.